Prospective mapping of viral mutations that escape antibodies used to treat COVID-19

Tyler N. Starr; Allison J. Greaney; Amin Addetia; William H. Hannon; Adam S. Dingens; Jesse D Bloom.
Preprint en Inglés | PREPRINT-BIORXIV | ID: ppbiorxiv-405472

Documentos relacionados

  1. Prospective mapping of viral mutations that escape antibodies used to treat COVID-19.
  2. Prospective mapping of viral mutations that escape antibodies used to treat COVID-19.
  3. Deep mutational scanning identifies SARS-CoV-2 Nucleocapsid escape mutations of currently available rapid antigen tests.
  4. A pseudovirus system enables deep mutational scanning of the full SARS-CoV-2 spike.
  5. Identification of broad, potent antibodies to functionally constrained regions of SARS-CoV-2 spike following a breakthrough infection.
  6. A natural mutation between SARS-CoV-2 and SARS-CoV determines neutralization by a cross-reactive antibody.
  7. Shared N417-Dependent Epitope on the SARS-CoV-2 Omicron, Beta, and Delta Plus Variants.
  8. Structure basis of two nanobodies neutralizing SARS-CoV-2 Omicron variant by targeting ultra-conservative epitopes.
  9. A Bispecific Antibody Targeting RBD and S2 Potently Neutralizes SARS-CoV-2 Omicron and Other Variants of Concern.
  10. Neutralization potency of monoclonal antibodies recognizing dominant and subdominant epitopes on SARS-CoV-2 Spike is impacted by the B.1.1.7 variant.